This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Apricus Biosciences Announces Podium Presentation Of Vitaros(R) Clinical Data At 2012 World Meeting On Sexual Medicine

SAN DIEGO, Aug. 20, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) ( today announced a podium presentation entitled, "Nine months treatment with alprostadil cream (Vitaros®) results in sustained improvement of erectile function in males suffering from erectile dysfunction," will take place on Tuesday, August 28, 2012, at 2:30 p.m. CT as part of the upcoming World Meeting on Sexual Medicine ("WMSM"), which will take place in Chicago, IL, on August 26-30, 2012. The presentation will discuss the results of a subpopulation analysis of an open label dose titration efficacy and safety study to support Vitaros ® at the dose of 300 mcg in 100 mg of cream.

This is the second Apricus Bio abstract accepted by the WMSM for presentation at this key medical industry meeting. On August 16, 2012, Apricus Bio announced that its abstract related to Femprox®, its drug candidate in development for female sexual arousal disorder ("FSAD"), had also been accepted as a podium presentation.

The Vitaros® (alprostadil 0.3% topical cream) data will be presented by Dr. Jacques Buvat, director of the Centre d'Etude et de Traitement de la Pathologie de l'Appareil Reproducteur et de la Psychosomatique (CETPARP) and a member of Apricus Bio's Vitaros® Clinical Advisory Board. Dr. Buvat is also a member of editorial boards for the International Journal of Impotence Research, Archivio Italiano Nephrologia Andrologia, Andrologie and Gynécologie Obstétrique Fertilité, chief editor of bulletins for the International Society for Sexual and Impotence Research and the French Société de Médecine de la Reproduction, president of the Association pour l'Etude et le Traitement de la Pathologie de l'Appareil Reproducteur et de la Psychomatique, and of the Association pour le Développement de l'Information et de la Recherche sur la Sexualité (ADIRS). He has written more than 300 scientific papers.

About Vitaros ®

Vitaros® is a topically delivered formulation of alprostadil delivered with Dodecyl 2-N, N-(dimethylamino)-propionate hydrochloride (DDAIP HCl), Apricus' proprietary NexACT® delivery technology, for the treatment of erectile dysfunction ("ED"). When absorbed through the skin, alprostadil, a vasodilator, directly boosts blood flow, thereby causing an erection.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,081.89 -49.97 -0.29%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,796.6090 -42.0340 -0.87%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs